Professor Jérôme Frenette is a researcher with a background in physical therapy and post-graduate training in muscle physiology and immunology at the University of California in Los-Angeles. He is a full-time researcher at the Centre de recherche du CHU de Québec-Laval University, and full professor in the department of rehabilitation at Laval University’s School of Medicine. He has been the principal investigator on several CIHR and NSERC grants. Many of his publications, and one CIHR grant were recognized and rewarded as being among the best in the field of muscle physiology. He started his career as a researcher by investigating the roles played by blood cells and mechanical loading in models of tendon injury and muscle atrophy/regrowth. In 2005, he expanded his research program to include the Buruli Ulcer, which is caused by mycobacterium ulcerans, a neglected disease of wet tropical zones, that is closely related to tuberculosis and leprosy. His research group was the first to show that mycobacterium ulcerans and its toxin, mycolactone, extend well beyond the skin, and severely affect underlying skeletal muscles. Today, the focus of his research program is to understand the link between osteoporosis and muscle atrophy/disease through one common pathway i.e. the RANK/RANKL/OPG pathway. In collaboration with Duchenne muscular dystrophy foundations in Canada, the United States and Australia, as well as sustainable financial support from public and private sources, his team is developing new drugs that would potentially alleviate, in tandem, osteoporosis and muscle degeneration in Duchenne muscular dystrophy patients or other forms of bone and muscle diseases.
2705, boulevard Laurier
Canada G1V 4G2
- Un projet mené par Sachiko Sato soutenu par la fondation Jesse’s Journey 2021-05-25
- Quatorze chercheurs du CRCHU reçoivent près de 9 millions de dollars de subvention des IRSC 2020-02-28
- Un sucre contre la dystrophie musculaire – Un supplément alimentaire dérivé du glucose produit des effets spectaculaires chez des souris atteintes de dystrophie musculaire de Duchenne 2018-06-28
- Argaw, AntenehEmployeeCHUL+1 418-525-4444, extension 48840Anteneh.Argaw@crchudequebec.ulaval.ca
2705, boulevard Laurier
Canada G1V 4G2
- Bouredji, ZinebDoctoral studentCHUL+1 418-525-4444, extension email@example.com@crchudequebec.ulaval.ca
2705, boul. Laurier
Canada G1V 4G2
Detection of S-100β Protein in Plasma and Urine After a Mild Traumatic Brain InjuryJournal Article
Can J Neurol Sci, 46 (5), 2019.
An anti-RANKL treatment reduces muscle inflammation and dysfunction and strengthens bone in dystrophic miceJournal Article
Hum Mol Genet, 28 (18), 2019.
Genetic deletion of muscle RANK or selective inhibition of RANKL is not as effective as full-length OPG-fc in mitigating muscular dystrophyJournal Article
Acta Neuropathol Commun, 6 (1), 2018.
Targeting the Muscle-Bone Unit: Filling Two Needs with One Deed in the Treatment of Duchenne Muscular DystrophyJournal Article
Curr Osteoporos Rep, 16 (5), 2018.
Utrophin haploinsufficiency does not worsen the functional performance, resistance to eccentric contractions and force production of dystrophic miceJournal Article
PLoS One, 13 (6), 2018.
Vitamin C is not the Missing Link Between Cigarette Smoking and Spinal PainJournal Article
Spine (Phila Pa 1976), 43 (12), 2018.
Prognostic Value of S-100β Protein for Prediction of Post-Concussion Symptoms after a Mild Traumatic Brain Injury: Systematic Review and Meta-AnalysisJournal Article
J Neurotrauma, 35 (4), 2018.
Galectin-3 and N-acetylglucosamine promote myogenesis and improve skeletal muscle function in the mdx model of Duchenne muscular dystrophyJournal Article
FASEB J, 2018.
Prognostic value of neuron-specific enolase (NSE) for prediction of post-concussion symptoms following a mild traumatic brain injury: a systematic reviewJournal Article
Brain Inj, 32 (1), 2018.
Deletion of the Fanconi Anemia C Gene in Mice Leads to Skeletal Anomalies and Defective Bone Mineralization and MicroarchitectureJournal Article
J Bone Miner Res, 33 (11), 2018.
- Decipher the physiological functions of osteoprotegerin in skeletal and cardiac muscles, from 2023-04-01 to 2028-03-31
- Development of a monosaccharide therapy using N-acetylglucosamine to mitigate Duchenne muscular dystrophy, from 2021-05-31 to 2024-05-30
- Multifunctional properties of osteoprotegerin in muscular dystrophy and muscle repair, from 2020-04-01 to 2025-03-31
Recently finished projects
- Deciphering the role of RANK/RANKL/OPG in skeletal muscle., from 2016-04-01 to 2022-03-31
- Development of a glycobiology therapy to mitigate the progression of Duchenne muscular dystrophy, from 2021-07-01 to 2023-02-28
- Does anti-RANKL therapy prevent glucocorticoid induced bone loss and promote muscle function in a mouse model of Duchenne muscular dystrophy, from 2021-04-01 to 2022-03-31
- Does anti-RANKL therapy prevent glucocorticoid induced bone loss in a mouse model of Duchenne muscular dystrophy?, from 2020-10-01 to 2021-07-31
- Investigation of the role of galectin-3 and its ligands in skeletal muscle strength, regeneration, and pathology, from 2018-10-01 to 2023-03-31
- La protéine S100B est-elle un outil de dépistage valide pour réduire le nombre de tomodensitométries inutiles suite à un traumatisme cranio-cérébral léger?, from 2017-04-01 to 2022-01-31